Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Minority Interest: 2015-2024

Historic Minority Interest for Fortress Biotech (FBIO) over the last 10 years, with Dec 2024 value amounting to -$24.4 million.

  • Fortress Biotech's Minority Interest rose 127.50% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 127.50%. This contributed to the annual value of -$24.4 million for FY2024, which is 16.34% down from last year.
  • As of FY2024, Fortress Biotech's Minority Interest stood at -$24.4 million, which was down 16.34% from -$21.0 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Minority Interest ranged from a high of $117.2 million in FY2021 and a low of -$24.4 million during FY2024.
  • In the last 3 years, Fortress Biotech's Minority Interest had a median value of -$21.0 million in 2023 and averaged -$12.3 million.
  • As far as peak fluctuations go, Fortress Biotech's Minority Interest spiked by 108.69% in 2020, and later tumbled by 352.37% in 2023.
  • Over the past 5 years, Fortress Biotech's Minority Interest (Yearly) stood at $96.7 million in 2020, then increased by 21.25% to $117.2 million in 2021, then slumped by 92.91% to $8.3 million in 2022, then plummeted by 352.37% to -$21.0 million in 2023, then dropped by 16.34% to -$24.4 million in 2024.